Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

USA - NASDAQ:XFOR - US98420X2027 - Common Stock

3.8 USD
+0.71 (+22.98%)
Last: 10/24/2025, 7:21:31 PM
3.87 USD
+0.07 (+1.84%)
After Hours: 10/24/2025, 7:21:31 PM
Fundamental Rating

2

Overall XFOR gets a fundamental rating of 2 out of 10. We evaluated XFOR against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of XFOR have multiple concerns. While showing a medium growth rate, XFOR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XFOR has reported negative net income.
In the past year XFOR has reported a negative cash flow from operations.
XFOR had negative earnings in each of the past 5 years.
In the past 5 years XFOR always reported negative operating cash flow.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

With a Return On Assets value of -96.96%, XFOR is not doing good in the industry: 75.09% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -2568.02%, XFOR is doing worse than 82.96% of the companies in the same industry.
Industry RankSector Rank
ROA -96.96%
ROE -2568.02%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Gross Margin of XFOR (83.00%) is better than 86.14% of its industry peers.
XFOR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
XFOR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for XFOR has been increased compared to 5 years ago.
Compared to 1 year ago, XFOR has a worse debt to assets ratio.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

XFOR has an Altman-Z score of -9.43. This is a bad value and indicates that XFOR is not financially healthy and even has some risk of bankruptcy.
XFOR's Altman-Z score of -9.43 is on the low side compared to the rest of the industry. XFOR is outperformed by 71.72% of its industry peers.
A Debt/Equity ratio of 19.10 is on the high side and indicates that XFOR has dependencies on debt financing.
XFOR's Debt to Equity ratio of 19.10 is on the low side compared to the rest of the industry. XFOR is outperformed by 83.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 19.1
Debt/FCF N/A
Altman-Z -9.43
ROIC/WACCN/A
WACC11.91%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 3.19 indicates that XFOR has no problem at all paying its short term obligations.
XFOR has a worse Current ratio (3.19) than 62.55% of its industry peers.
XFOR has a Quick Ratio of 3.05. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
XFOR has a Quick ratio of 3.05. This is in the lower half of the industry: XFOR underperforms 60.86% of its industry peers.
Industry RankSector Rank
Current Ratio 3.19
Quick Ratio 3.05
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for XFOR have decreased strongly by -12.35% in the last year.
Looking at the last year, XFOR shows a very strong growth in Revenue. The Revenue has grown by 5721.31%.
EPS 1Y (TTM)-12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.24%
Revenue 1Y (TTM)5721.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%250.44%

3.2 Future

XFOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.51% yearly.
XFOR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 127.57% yearly.
EPS Next Y82.32%
EPS Next 2Y37.36%
EPS Next 3Y24.65%
EPS Next 5Y14.51%
Revenue Next Year1511.73%
Revenue Next 2Y206.53%
Revenue Next 3Y267.06%
Revenue Next 5Y127.57%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XFOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as XFOR's earnings are expected to grow with 24.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.36%
EPS Next 3Y24.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XFOR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (10/24/2025, 7:21:31 PM)

After market: 3.87 +0.07 (+1.84%)

3.8

+0.71 (+22.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners82.93%
Inst Owner Change-0.08%
Ins Owners7.77%
Ins Owner Change9.91%
Market Cap43.36M
Revenue(TTM)32.77M
Net Income(TTM)-101976000
Analysts83.64
Price Target8.87 (133.42%)
Short Float %18.18%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.23%
Min EPS beat(2)21.58%
Max EPS beat(2)100.88%
EPS beat(4)2
Avg EPS beat(4)27.08%
Min EPS beat(4)-12.04%
Max EPS beat(4)100.88%
EPS beat(8)4
Avg EPS beat(8)-140.1%
EPS beat(12)6
Avg EPS beat(12)-99.51%
EPS beat(16)7
Avg EPS beat(16)-77.16%
Revenue beat(2)2
Avg Revenue beat(2)666.75%
Min Revenue beat(2)20.01%
Max Revenue beat(2)1313.49%
Revenue beat(4)3
Avg Revenue beat(4)325.24%
Min Revenue beat(4)-67.57%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-79.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)70.62%
EPS NY rev (1m)23.15%
EPS NY rev (3m)61.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.32
P/FCF N/A
P/OCF N/A
P/B 10.92
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.83
EYN/A
EPS(NY)-2.41
Fwd EYN/A
FCF(TTM)-9.85
FCFYN/A
OCF(TTM)-9.58
OCFYN/A
SpS2.87
BVpS0.35
TBVpS-2.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.96%
ROE -2568.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 19.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.52%
Cap/Sales 9.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.19
Quick Ratio 3.05
Altman-Z -9.43
F-Score1
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.24%
EPS Next Y82.32%
EPS Next 2Y37.36%
EPS Next 3Y24.65%
EPS Next 5Y14.51%
Revenue 1Y (TTM)5721.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%250.44%
Revenue Next Year1511.73%
Revenue Next 2Y206.53%
Revenue Next 3Y267.06%
Revenue Next 5Y127.57%
EBIT growth 1Y14.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.59%
OCF growth 3YN/A
OCF growth 5YN/A

X4 PHARMACEUTICALS INC / XFOR FAQ

What is the ChartMill fundamental rating of X4 PHARMACEUTICALS INC (XFOR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to XFOR.


What is the valuation status of X4 PHARMACEUTICALS INC (XFOR) stock?

ChartMill assigns a valuation rating of 1 / 10 to X4 PHARMACEUTICALS INC (XFOR). This can be considered as Overvalued.


What is the profitability of XFOR stock?

X4 PHARMACEUTICALS INC (XFOR) has a profitability rating of 1 / 10.